Search results (340)
« Back to NewsStudy shows urgent change needed to reduce deaths from malaria and meningitis in comatose African children
22 April 2025
Results of two parallel studies show that one in four African children hospitalised with malaria and coma have an additional infection, and that giving antibiotics with antimalarials could help reduce death rates of comatose children.
Spotlight on Magdalen College Chapel for Rare Disease Day
28 February 2025
The chapel facade of Magdalen College was lit up ahead of the commemoration of Rare Disease Day (RDD) which was celebrated on Friday 28th February 2025. The celebration is held on 29th February in a leap year as it is the rarest day in the year.
New partnership to advance public health and life science research collaboration in West Africa
13 February 2025
The Pandemic Sciences Institute, including principal investigators from the Oxford Vaccine Group, has signed a memorandum of understanding with Institut Pasteur de Dakar (IPD) to become a partner institution. PSI and Institut Pasteur de Dakar (IPD) will cooperate on developing vaccines and rapid diagnostics – as well as strengthening workforce in the vaccinology, clinical trials and biomanufacturing sectors.
New study shows that early support for children living in marginalised communities can improve their developmental outcomes
29 January 2025
Research by experts at the Department of Paediatrics, and published in the European Journal of Paediatrics shows that early interventions of support to the development of children living in disadvantaged settings, can significantly improve their neurodevelopmental outcomes during early childhood.
Oxford and partners lead on two new MRC Centres to create cutting-edge gene therapies
11 December 2024
Oxford University researchers are to lead and co-lead on two MRC research centres, which are being launched to develop new advanced treatments for currently untreatable diseases.
Trial results for first vaccine against blood-stage malaria show it is well-tolerated and offers effective protection
10 December 2024
Results of a clinical trial into a new malaria vaccine candidate (RH5.1/Matrix-M) show it is well-tolerated and offers effective protection against the blood-stage of the disease – the first inoculation to do so.
Dr. Nicky Whiffin awarded Balfour Lecture 2025
22 November 2024
Nicky Whiffin, Associate Professor and Sir Henry Dale Fellow at the University of Oxford’s Big Data Institute and Centre for Human Genetics, has been awarded the 2025 Balfour Lecture by the Genetics Society.
University of Oxford unveils new vaccine development partnership
15 November 2024
Oxford Cancer, the Oxford Vaccine Group and the Pandemic Sciences Institute have announced a new collaboration with Belgian Biotech Innovator, Univercells.
Ineos Oxford Institute makes award to OVG project tackling antimicrobial resistance
28 October 2024
The Ineos Oxford Institute for antimicrobial research (IOI) has awarded over £2m to six projects across the University of Oxford focused on developing new solutions to tackle antimicrobial resistance (AMR), including one at the Oxford Vaccine Group.
David Cameron resumes role as chair of Advisory Council for Oxford-Harrington Rare Disease Centre (OHC)
16 October 2024
Former UK Prime Minister David Cameron has resumed his role as chair of the OHC Advisory Council, a position he originally undertook in October 2023 prior to his appointment as Foreign Secretary.
Typhoid vaccine trial confirms sustained protection for older children
10 October 2024
A single dose of typhoid conjugate vaccine (TCV) offers safe, effective protection against typhoid two years after vaccination in all children, and sustained protection for older children at three to five years post immunisation, according to a report by researchers at the Oxford Vaccine Group and icddr,b. But it also shows a decline in protection at the later timepoints among children vaccinated at younger ages.
New campaign launched to encourage vaccine uptake
30 September 2024
Oxford Vaccine Group marks 30 years battling ‘deadly six’ diseases with major art installation
30 September 2024
A major art installation featuring dramatically upscaled bacteria, viruses and a parasite has been unveiled at Oxford University’s Museum of Natural History to celebrate 30 years of vaccine development by the Oxford Vaccine Group (OVG) which has tackled some of the world’s most deadly diseases.
Launch of new podcast series Trusting the Science
19 September 2024
The Oxford Vaccine Group is celebrating 30 years of life-saving vaccine development with the release of a new podcast series of conversations called Trusting the Science. This is the second series of The Oxford Colloquy - discourses hosted by Professor Sir Andrew Pollard who has been Director of the group for over 20 years - and each episode delves into the crucial role that science plays in our understanding of health and immunity.
Athena Swan Gold award
9 September 2024
The Department of Paediatrics has been awarded the Athena Swan Gold award for its commitment to advancing gender equality in higher education. Established in 2005 to encourage and recognise commitment to advancing the careers of women in science, technology, engineering, maths and medicine (STEMM) employment, the Charter is now used across the globe to address gender equality and barriers to progression that affect women.
New research identifies autoimmunity against a key anti-inflammatory regulator in inflammatory bowel disease
4 August 2024
- Clinical Trials
- Department
- Gastroenterology
- Immunology
- Publication
- Research
- Research Methods
- University
A ground-breaking study, published by the New England Journal of Medicine, has identified a new disease-inducing mechanism for inflammatory bowel disease (IBD) in which the immune system attacks its own regulatory function.
Oxford scientists launch first-in-human vaccine trial for deadly Marburg virus
12 July 2024
Scientists at the University of Oxford have launched a new clinical trial to test a vaccine to protect people against deadly Marburg virus.
New discovery renews hope for thousands with neurodevelopment disorders
12 July 2024
A global collaboration led by scientists at the University of Oxford has discovered that genetic variants in a specific gene cause a rare neurodevelopmental disorder (NDD). NDD is a collective term for severe impairments in how the brain functions that impact learning, behaviour, speech, and movement. Most NDDs are thought to be genetic and caused by changes to DNA, however, to date, around 60% of individuals with these conditions do not know the specific DNA change that causes their disorder.
New trial launches for two-in-one vaccine to prevent RSV and hMPV
12 July 2024
Scientists at the University of Oxford have launched a phase 1 study to test two investigational mRNA vaccines: one for both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) and a second for RSV alone in infants aged five to eight months old. The vaccines are being developed by Moderna.
Research shows early life immunity increases HIV cure/remission in male infants
10 June 2024
New research published by scientists at the University of Oxford, the University of KwaZulu-Natal and the Africa Health Research Institute in South Africa, and the Ragon Institute of Mass General, MIT and Harvard, USA, shows that male infants are more likely to achieve HIV cure/remission than females.